KRAS mutations are among the most prevalent tumor drivers, but targeting them pharmacologically has been challenging. Recent landmark studies have demonstrated promising clinical results of KRASG12C inhibition by using small molecules. Bar-Sagi, and Knelson and Sequist provide their distinct perspectives on this recent tour de force in targeting KRASG12C alterations.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Molecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort
Diagnostic Pathology Open Access 10 June 2023
-
Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting
BMC Cancer Open Access 17 April 2023
-
Peptidomimetics designed to bind to RAS effector domain are promising cancer therapeutic compounds
Scientific Reports Open Access 22 September 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ostrem, J. M. & Shokat, K. M. Nat Rev. Drug Discov. 15, 771–785 (2016).
Canon, J. et al. Nature 575, 217–223 (2019).
Hallin, J. et al. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-19-1167 (2019).
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. Nature 503, 548–551 (2013).
Castellano, E. & Downward, J. Genes Cancer 2, 261–274 (2011).
Cullis, J., Das, S. & Bar-Sagi, D. Cold Spring Harb. Perspect. Med. 8, a031849 (2018).
Fakih, M., O’Neil, B. & Price, T. J. J. Clin. Oncol. 37 (Suppl.), abstr. 3003 (2019).
Govindan, R. et al. Ann. Oncol. 30 (Suppl. 5), mdz244.008 (2019).
Hosomi, Y. et al. J. Clin. Oncol. https://doi.org/10.1200/JCO.19.01488 (2019).
Matikas, A., Mistriotis, D., Georgoulias, V. & Kotsakis, A. Crit. Rev. Oncol. Hematol. 110, 1–12 (2017).
Planchard, D. et al. Lancet Oncol. 18, 1307–1316 (2017).
Sequist, L. V. et al. Cancer Res. 79, abstr. CT033 (2019).
Arbour, K. C. et al. Clin. Cancer Res. 24, 334–340 (2018).
Oxnard, G. R. et al. J. Clin. Oncol. 33 (Suppl.), abstr. 2509 (2015).
Jänne, P. A. in AACR-NCI-EORTC International Conf. on Molecular Targets and Cancer Therapeutics (2019); https://www.mirati.com/wp-content/uploads/2019/10/AACR-NCI-EORTC-Clinical-Data-Presentation_Janne_October-2019-1-1.pdf
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Bar-Sagi, D., Knelson, E.H. & Sequist, L.V. A bright future for KRAS inhibitors. Nat Cancer 1, 25–27 (2020). https://doi.org/10.1038/s43018-019-0016-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-019-0016-8
This article is cited by
-
Molecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort
Diagnostic Pathology (2023)
-
Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting
BMC Cancer (2023)
-
Peptidomimetics designed to bind to RAS effector domain are promising cancer therapeutic compounds
Scientific Reports (2022)
-
miR-34c-3p targets CDK1 a synthetic lethality partner of KRAS in non-small cell lung cancer
Cancer Gene Therapy (2021)
-
Post-translational modification of KRAS: potential targets for cancer therapy
Acta Pharmacologica Sinica (2021)
